Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in MASH diagnosis and care.

Noninvasive alternatives are beginning to become more accessible, however, and Echosens, the developer of one such offering, is on a quest to use its technology to vastly increase NASH screening.

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next ...

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...

DIMO Healthcare, a leader in the Sri Lankan healthcare sector, has introduced the country’s first Echosens FibroScan® Expert ...

PARIS, Aug. 26, 2024 /PRNewswire/ -- Echosens is thrilled to unveil the inaugural Liver Health Super Shaper Award, a heartfelt initiative designed to celebrate the extraordinary medical ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

At Boehringer, we're committed to being part of the solution, and the expansion of our partnership with Echosens is one we're particularly excited about. We look forward to working together to ...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, ...